"In the second quarter, we achieved a key milestone for Prime Medicine and our next-generation gene editing technology, securing clearance from the U.S. Food and Drug Administration (FDA) to advance PM359, our Prime Editor for the treatment of chronic granulomatous disease (CGD), into the clinic. We are now in the process of initiating our Phase 1/2 clinical trial, and we look forward to sharing initial clinical data in 2025," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "As we mature into a clinical-stage company, I am particularly excited to announce Dr. Mohammed Asmal's promotion to Chief Medical Officer. Since joining Prime Medicine in 2022, Mohammed has been a valuable member of our leadership team, helping shepherd PM359 to an investigational new drug (IND) acceptance and Prime's first clinical trial, and leading our clinical development strategy across our portfolio more broadly.